Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30010176HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30011515HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30005768HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30029331HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30029332HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30029333HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30029334HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30029335HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30029336HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TVIS30029337HIVENSG00000026508.21protein_codingCD44NoNo960P16070
TCGA Plot Options
Drug Information
GeneCD44
DrugBank IDDB06550
Drug NameBivatuzumab
Target IDBE0001113
UniProt IDP16070
Regulation Type
PubMed IDs14530488
CitationsPostema EJ, Borjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ: Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med. 2003 Oct;44(10):1690-9.
GroupsInvestigational
Direct ClassificationPeptides
SMILES
Pathways
PharmGKB
ChEMBL